|
SCYL3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.29609664614827E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.05649991164614E-10 |
| Normal-vs-Stage2 |
3.63589999996528E-06 |
| Normal-vs-Stage3 |
2.12930000298428E-08 |
| Normal-vs-Stage4 |
3.28510000313642E-08 |
| Stage1-vs-Stage2 |
5.845800E-01 |
| Stage1-vs-Stage3 |
6.667400E-01 |
| Stage1-vs-Stage4 |
2.718400E-01 |
| Stage2-vs-Stage3 |
8.359000E-01 |
| Stage2-vs-Stage4 |
6.995200E-01 |
| Stage3-vs-Stage4 |
4.810400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.97160107421269E-11 |
| Normal-vs-AfricanAmerican |
7.200900E-03 |
| Normal-vs-Asian |
3.01449999995373E-06 |
| Caucasian-vs-AfricanAmerican |
1.540620E-01 |
| Caucasian-vs-Asian |
7.770400E-01 |
| AfricanAmerican-vs-Asian |
2.466000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.59579996281434E-09 |
| Normal-vs-Female |
1.16940013228373E-10 |
| Male-vs-Female |
8.859200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.1448000587252E-10 |
| Normal-vs-Age(41-60Yrs) |
8.22900003694116E-09 |
| Normal-vs-Age(61-80Yrs) |
5.28039999947438E-07 |
| Normal-vs-Age(81-100Yrs) |
1.039340E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.627800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.835200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.561800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.820600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.550600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.442200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.792100E-02 |
| Classical-VS-Follicular |
2.722100E-02 |
| Classical-VS-Other |
5.114400E-01 |
| Classical-VS-Normal |
6.31130003814206E-09 |
| Tall-VS-Follicular |
8.392800E-01 |
| Tall-VS-Other |
7.311600E-01 |
| Tall-VS-Normal |
4.85840000452598E-08 |
| Follicular-VS-Other |
8.673600E-01 |
| Follicular-VS-Normal |
2.03890000438633E-08 |
| Other-VS-Normal |
1.321540E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.02580000049812E-09 |
| Normal-vs-N1 |
4.53709999570506E-08 |
| N0-vs-N1 |
4.280000E-01 |
|
|
